<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25252">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151214</url>
  </required_header>
  <id_info>
    <org_study_id>ALIM-K</org_study_id>
    <nct_id>NCT02151214</nct_id>
  </id_info>
  <brief_title>Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.</brief_title>
  <acronym>ALIM-K</acronym>
  <official_title>Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de cancérologie de Lorraine, Vandoeuvre les Nancy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Paul Strauss</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Jean-Godinot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In malnourished patients in the palliative phase of cancer, the question is raised of the
      relevance of implementing artificial nutritional assistance instead of oral feeding when
      this is possible.

      Medical prescription and implementation of artificial nutrition at this stage of the illness
      seem less governed by data acquired by science than by subjective reasons (related to
      beliefs, to a cultural or religious tradition, to the symbolic role of eating, to the deeply
      ingrained fear of dying of hunger, to a portrayal of care, etc.) while interacting with
      teams, the patient and his family and relatives.

      And yet, the benefits/risk balance and the effect on quality of life of parenteral nutrition
      in a palliative situation for patients presenting with a normal alimentary tract is poorly
      understood. The discomfort and risks of central venous or nasogastric artificial nutrition
      require that the benefits of artificial nutrition be proven.  The nature of these benefits
      relate first and foremost to the quality of life experienced by the patient in such a
      context. Only a controlled randomized study may lead to an optimal palliative nutritional
      management of undernutrition to be determined, and to inform the patient and his/her
      relatives clearly in order for them to express their preferences.

      We hypothesize that abstaining from artificial parenteral central venous nutrition and
      associated  hydration for nutritional purposes improves quality of life without significant
      loss of survival compared to implementing artificial nutrition, when considered, in the
      absence of any specific curative treatment in anorexic patients in the palliative phase of
      cancer.

      To test this hypothesis, we propose to carry out a  multicenter, prospective, controlled,
      randomized study in order to evaluate the efficacy of implementing parenteral nutrition
      compared to abstaining from doing so on the quality of life of undernourished patients in
      the palliative phase of cancer. The effect on overall survival and the nutritional
      parameters will be evaluated.

      The ALIM K trial will be carried out in 10 centres specializing in supportive and
      onco-hematology care .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>QLQ-C15-Pal to assess Quality of Life through the physical functioning, Global Health Status and fatigue subscales</measure>
    <time_frame>At day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>The EORTC -The European Organisation for Research and Treatment of Cancer QLQ-C15-Pal - Quality of Life Questionnaire Core 15 Palliative is used.
Physical functioning, global health status and fatigue are compared between the 2 groups at day 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QUAL-E Measuring Quality of Life at the end of Life</measure>
    <time_frame>At day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionaire for patients who believe they are nearing the end of life and comparison between the 2 groups at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomization to death</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of overall survival between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C15-Pal to assess Quality of Life through the emotional functioning and nausea/vomiting subscales</measure>
    <time_frame>At day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the emotional functioning and nausea/vomiting subscales between the 2 groups at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C15-Pal to assess Quality of life through the longitudinal analysis of its 5 subscales</measure>
    <time_frame>At day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Longitudinal analysis of the 5 subscales:
Physical functioning, emotional functioning, global health status, fatigue, nausea/vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>At day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total body weight will be compared between the 2 groups at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin in blood</measure>
    <time_frame>at day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>albumin in blood will be compared between the 2 groups at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pre-albumin in blood</measure>
    <time_frame>at day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>pre-albumin in blood will be compared between the 2 groups at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein in blood</measure>
    <time_frame>at day 60</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>C-Reactive Protein in blood will be compared between the 2 groups at day 60.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Nutrition Aspect of Cancer</condition>
  <condition>End Stage Cancer</condition>
  <arm_group>
    <arm_group_label>Parenteral nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition will be administered to the patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal per os nutrition</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will eat orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <description>Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted</description>
    <arm_group_label>Parenteral nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are:

          -  adult patients (aged &gt;18 years) suffering from cancer at the palliative stage, i.e.
             patients in whom the main aim of treatment is to limit pain and discomfort

          -  curative treatment has either been discontinued, or may still be ongoing but with
             little expected benefit in terms of overall survival

          -  Life expectancy must be longer than 2 months

          -  patients must have a functional digestive tract

          -  present malnutrition defined as a body mass index (BMI) &lt;18.5 kg/m² in patients aged
             &lt;70 years or &lt;21 kg/m² in patients aged ≥70 years; or weight loss of 2% in 1 week, 5%
             in 1 month, or 10% in 6 months

          -  Patients with antalgic radiotherapy or scheduled to undergo palliative surgery

          -  Patients must already have a functional central venous catheter in place

        Exclusion Criteria:

          -  non-functional digestive tract (intestinal occlusion, tumor compression, subocclusive
             peritoneal carcinosis);

          -  any disorder preventing oral ingestion (cancer of the upper aerodigestive tract,
             oesophagus or stomach);

          -  parenteral nutrition that is ongoing or dating from less than one month;

          -  intravenous chemotherapy through a pump lasting &gt;48 hours as this is incompatible
             with administration of parenteral nutritional through the central venous line;

          -  presence of gastrostomy or jejunostomy;

          -  persisting sensation of hunger in aphagic patients

          -  patients with haematological cancers undergoing bonemarrow transplant,

          -  patients with acute renal failure (defined as creatinine clearance &lt; 30 ml/min) or
             heart failure (defined as a left ventricular ejection fraction &lt;30%);

          -  adult patients under legal guardianship

          -  unable to respond to the quality of life questionnaire (due to psychiatric disorders,
             attention disorders, or cognitive disorders)

          -  Patients participating in another ongoing clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regis Aubry, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Régis AUBRY</last_name>
    <phone>+33381668069</phone>
    <email>raubry@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile CORNET</last_name>
    <phone>+33381218682</phone>
    <email>ccornet@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Palliative Care Unit - CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis AUBRY</last_name>
      <phone>+33381668069</phone>
      <email>raubry@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile CORNET</last_name>
      <phone>+33381218682</phone>
      <email>ccornet@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Régis AUBRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas BECOULET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile BESSET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine THIERRY-VUILLEMIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sorya LY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Tournigand, Dr</last_name>
      <email>christophe.tournigand@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Tournigand, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Gamblin, Dr</last_name>
      <phone>+33 20 29 59 59</phone>
      <email>V-Gamblin@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Gamblin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisèle Chvetzoff, Dr</last_name>
      <phone>+33 4 78 78 26 57</phone>
      <email>chvetzoff@lyon.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Gisèle Chvetzoff, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine Capodano, Dr</last_name>
      <email>capodanog@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Géraldine Capodano, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Bouleuc, MD</last_name>
      <phone>+331 44 32 41 38</phone>
      <email>carole.bouleuc@curie.net</email>
    </contact>
    <investigator>
      <last_name>Carole Bouleuc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Dubroeucq, Dr</last_name>
      <email>olivier.dubroeucq@reims.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Dubroeucq, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Frasie, Dr</last_name>
      <phone>+33 88 25 85 92</phone>
      <email>JMFrasie@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel Frasie, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathie Fischbach, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Crétineau, Dr</last_name>
      <phone>+33 83 59 84 86</phone>
      <email>n.cretineau@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Crétineau, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Raynard, Dr</last_name>
      <phone>+33 1 42 11 40 53</phone>
      <email>bruno.raynard@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Raynard, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Régis AUBRY</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <keyword>Palliative Phase of Cancer</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Parenteral nutrition</keyword>
  <keyword>Undernutrition</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
